- Home
- INTR vs VRDN Comparison
INTR vs VRDN Comparison
Compare INTR & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INTR | VRDN |
|---|---|---|
| Founded | 1994 | 2006 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.1B |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | INTR | VRDN |
|---|---|---|
| Price | $5.59 | $23.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 14 |
| Target Price | $10.00 | ★ $35.46 |
| AVG Volume (30 Days) | ★ 5.6M | 1.6M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.51% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,706,000.00 |
| Revenue This Year | $84.07 | $13.73 |
| Revenue Next Year | $18.26 | $279.00 |
| P/E Ratio | $16.39 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.04 | $13.18 |
| 52 Week High | $10.36 | $34.29 |
Technical Indicators
Market Signals| Indicator | INTR | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 55.34 | 55.42 |
| Support Level | $5.22 | $21.62 |
| Resistance Level | $5.96 | $24.86 |
| Average True Range (ATR) | 0.24 | 0.77 |
| MACD | 0.04 | -0.23 |
| Stochastic Oscillator | 73.72 | 43.52 |
Price Performance
Historical ComparisonAbout INTR Inter & Co. Inc.
Inter & Co Inc operates as a digital bank. The company's segment includes Banking & Spending; Investments; Insurance Brokerage; and Inter Shop. It generates maximum revenue from the Banking & Spending segment which comprises a wide range of banking products and services, such as checking accounts, cards, deposits, loans and advances, and other services, which are available to the clients by means of Inters mobile application.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.